Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan's Freedom From Expression Suit Challenges Gov't REMS, Off-Label Powers

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm wants to go beyond the REMS requirements and offer treatment guidance, not just risk information, about the use of Botox for spasticity, an unapproved condition.

You may also be interested in...



Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ

Allergen will pay $600 million for promoting the drug for headache and spasticity; government says company taught physicians how to bill for off-label uses.

Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ

Allergen will pay $600 million for promoting the drug for headache and spasticity; government says company taught physicians how to bill for off-label uses.

Waxman Staffer Ann Witt Rejoining FDA

The former DDAMC head will bring wide knowledge of promotion and follow-on biologic issues to policy discussions.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel